Form 4: Checkpoint Therapeutics CFO Acquires 500,000 Shares of Restricted Stock

Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, acquired 500,000 shares of restricted stock on January 30, 2025.

Summary

• William Garrett Gray, the Chief Financial Officer of Checkpoint Therapeutics, acquired 500,000 shares of restricted common stock on January 30, 2025.
• The shares were granted at a price of $0.
• These shares vest in three equal installments: one-third on January 30, 2026, one-third on January 30, 2027, and the final third on January 30, 2028.
• Following this transaction, Mr. Gray's total holdings include 1,532,754 shares of common stock, including previously granted restricted shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The grant of restricted stock is a common practice and does not indicate any negative sentiment.

Positives

• The acquisition of shares by the CFO could be seen as a positive sign of confidence in the company's future.

Industry Context

This type of stock grant is a common practice for incentivizing and retaining key executives in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Stock grants to executives are a standard practice in the biotech industry, often used to align management's interests with those of shareholders.
• The vesting schedule of one-third per year over three years is a typical vesting structure for restricted stock grants.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar equity compensation plans for their executives.

Stakeholder Impact

• The stock grant could positively impact shareholder confidence by demonstrating the CFO's commitment to the company's long-term success.
• The vesting schedule ensures the CFO's continued engagement with the company over the next three years.

Key Dates

Keywords

Checkpoint Therapeutics, CKPT, restricted stock, insider trading, William Garrett Gray, CFO, equity compensation, share ownership